Clinical Recruitment of Patients With First-line Targeted Drug Resistance or Intolerance to Hepatocellular Cancer With PD-1 Inhibitor (Toripalimab,JS001) Detected on the NGS Platform Combined With Anlotinib

Inclusion Criteria:

1. Histological or cytological diagnosis of hepatocellular cancer;
2. At least one measurable lesion was assessed according to RECIST1.1 criteria.
3. Age from 18 to 75,ECOG physical strength score reaches 0-2;
4. After first-line targeted therapy, it was assessed as advanced or intolerant according to RECIST1.1 criteria.
5. Child-pugh grade A or B for liver function;
6. Bone marrow function was basically normal: neutrophils > 1.5x 10^9/L, platelets > 75 x10^9/L;
7. Adequate renal reserve: creatinine <130 mol/L;
8. Centerless dysfunction, chest pain (medically uncontrollable), no myocardial infarction within 12 months prior to study initiation;
9. Estimated survival ≥3 months;
10. Signed the informed consent.

Exclusion Criteria:

1. Previous application of PD-1 inhibitor and anlotinib;
2. Secondary malignant tumors or other tumors (except superficial skin cancer and localized low-grade malignant tumors) occurring within 3 years prior to the start of the study;
3. Metastasis of the brain or meninges;
4. Imaging findings indicated that the tumor was involved in important blood vessels or that the researchers had assessed that it might lead to fatal bleeding during follow-up;
5. Bleeding events at any site ≥CTCAE level 3 occurred 4 weeks before medication, and there were unhealed wounds, ulcers or fractures;
6. The time of occurrence of arteriovenous thrombosis, such as cerebrovascular accident, deep vein thrombosis and pulmonary embolism, within 6 months before enrollment;
7. Untreated intestinal obstruction or subobstruction that cannot eat or affect systemic administration;
8. Patients with active infection or other possible disorders receive inflammatory infections under planned management;
9. Have a history of uncontrolled substance abuse or mental disorders;
10. In the judgment of the investigator, patients with concomitant diseases that may seriously endanger their own safety or may affect the completion of the study;
11. Participated in other clinical trials;
12. Pregnant and nursing women;